Literature DB >> 20436503

Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.

D Craig Allred1.   

Abstract

There are currently three prognostic/predictive biomarkers used in routine clinical management of patients with breast cancer, and their assessment is mandatory. They include estrogen receptor-alpha (ERalpha), progesterone receptor (PgR), and the HER2 oncogene/oncoprotein. This paper briefly reviews the assessment of ERalpha, PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20436503     DOI： 10.1038/modpathol.2010.55

Source DB:  PubMed          Journal:  Mod Pathol        ISSN： 0893-3952            Impact factor:   7.842


  49 in total

Review 1.  Identifying and targeting tumor-initiating cells in the treatment of breast cancer.

Authors:  Wei Wei; Michael T Lewis
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

2.  ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.

Authors:  Semir Vranic; Zoran Gatalica; Hao Deng; Snjezana Frkovic-Grazio; Lisa M J Lee; Olga Gurjeva; Zhao-Yi Wang
Journal:  J Clin Pathol       Date:  2010-11-02       Impact factor: 3.411

Review 3.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

4.  Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study.

Authors:  Wynton B Overcast; Jianying Zhang; Debra L Zynger; Gary H Tozbikian
Journal:  Virchows Arch       Date:  2016-05-25       Impact factor: 4.064

Review 5.  Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.

Authors:  Atsuko Yoneda; Maria E Lendorf; John R Couchman; Hinke A B Multhaupt
Journal:  J Histochem Cytochem       Date:  2012-01       Impact factor: 2.479

6.  Clinical implications of ERβ methylation on sporadic breast cancers in Chinese women.

Authors:  Lin Zhao; Zhaojin Yu; Yunan Li; Xiaoyan Wen; Wenfeng Ma; Lin Wang; Jie Ren; Caigang Liu; Miao He; Xuefeng Bai; Mingli Sun; Zhihong Zheng; Xiaoyi Mi; Enhua Wang; Olufunmilayo I Olopade; Feng Jin; Minjie Wei
Journal:  Med Oncol       Date:  2011-11-22       Impact factor: 3.064

Review 7.  Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate.

Authors:  Frederik Holst
Journal:  World J Clin Oncol       Date:  2016-04-10

8.  P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis.

Authors:  Robin Fuchs-Young; Stephanie H Shirley; Isabel Lambertz; Jennifer K L Colby; Jie Tian; Dennis Johnston; Irma B Gimenez-Conti; Lawrence A Donehower; Claudio J Conti; Stephen D Hursting
Journal:  Breast Cancer Res Treat       Date:  2010-12-30       Impact factor: 4.872

9.  Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.

Authors:  Dara S Ross; Ahmet Zehir; Edi Brogi; Fumiko Konno; Melissa Krystel-Whittemore; Marcia Edelweiss; Michael F Berger; Weiyi Toy; Sarat Chandarlapaty; Pedram Razavi; José Baselga; Hannah Y Wen
Journal:  Mod Pathol       Date:  2018-08-29       Impact factor: 7.842

Review 10.  Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy.

Authors:  Jacek Capala; Kirsten Bouchelouche
Journal:  Curr Opin Oncol       Date:  2010-11       Impact factor: 3.645
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.